Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Company Growth (employees)
Type
Public
HQ
Bagsvaerd, DK
Founded
1923
Size (employees)
42,076 (est)+2%
Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, DK

Key People/Management at Novo Nordisk

Lars Rebien Sørensen

Lars Rebien Sørensen

President & Chief Executive Officer
Jesper Brandgaard

Jesper Brandgaard

EVP and Chief Financial Officer
Maziar Mike Doustdar

Maziar Mike Doustdar

EVP of International Operations
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

EVP Corporate Developemnt

Novo Nordisk Office Locations

Novo Nordisk has offices in Bagsvaerd, Plainsboro, Mississauga, Mainz and in 137 other locations
Mississauga, CA
300-2680 Skymark Avenue, Floor 3
Beijing, CN
18F, East Tower, World Financial Center, No. 1 East 3rd Ring Middle Road, Chaoyang District
Mainz, DE
Brucknerstrasse 1
Bangalore, IN
Plot No.32, 47-50, EPIP Area, Whitefield
Tokyo, JP
Meiji Yasuda Seimei Bldg. 2-1-1, Marunouchi, Chiyoda-ku
AV Alphen aan den Rijn, NL
Flemingweg 18
Show all (141)

Novo Nordisk Financials and Metrics

Novo Nordisk Financials

USD

Market capitalization (31-Oct-2017)

123.5 b

Closing share price (31-Oct-2017)

49.9
Novo Nordisk's current market capitalization is $123.5 b.
Show all financial metrics

Novo Nordisk Operating Metrics

FY, 2015FY, 2016

Phase III Trials

63

Projects in R&D Pipeline

1917

Patients Reached

26.8 m
Show all operating metrics

Novo Nordisk Market Value History

Novo Nordisk Median Salaries

Source: 33 public H-1B filings from Novo Nordisk
Show all human capital metrics

Novo Nordisk's Web-traffic and Trends

Novo Nordisk Online and Social Media Presence

Novo Nordisk News and Updates

Novo Nordisk secures Ozempic formulary coverage from Express Scripts

Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts, an important step in the early stages of the drug's launch.

Novo Nordisk trumpets first phase 3 oral semaglutide results. Does Lilly need to worry yet?

Highly anticipated phase 3 results for Novo Nordisk’s oral GLP-1 diabetes therapy, semaglutide, are here, and investors of Novo rival Eli Lilly are taking note.

Insulin Delivery Systems 2018 Global Market Key Players -Novo Nordisk, West Pharma, Beta Bionics, Copernicus, MannKind -Analysis And Forecast To 2022

Wiseguyreports.Com Adds “Insulin Delivery Systems – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Hard-hit Novo Nordisk still has M&A 'on the radar' post-Ablynx setback, CEO says

Let’s just say it hasn’t been a great week for Novo Nordisk. After losing out to higher bidder Sanofi on a buyout of Ablynx, the Danish drugmaker Thursday rolled out fourth-quarter results and 2018 guidance that Oddo BHF analyst Sebastien Malafosse called “disappointing” in a note to clients.

Novo Nordisk teams with 'Black-ish' star Anthony Anderson for small-screen diabetes diagnosis

Actor Anthony Anderson is a comedian, but when it comes to diabetes, he is a serious advocate. He's partnered with Novo Nordisk to create the “Get Real About Diabetes” disease awareness campaign, and as part of that effort he wrote a Type 2 diabetes diagnosis episode into the plot of his hit comedy …

Novo Nordisk preps big obesity push, undeterred by its rivals' failures

Novo Nordisk is about to take on a task that’s so far foiled its peers. The Danish drugmaker is aiming to expand the global obesity market, both by launching its GLP-1 drug Saxenda in additional countries and by lobbying to get obesity recognized as a chronic disease.
Show more

Novo Nordisk Company Life and Culture

You may also be interested in